key: cord-0731152-4idl223r
authors: Zimmermann, Tobias; Walter, Joan Elias; Lopez‐Ayala, Pedro; Strebel, Ivo; Amrein, Melissa; Koechlin, Michael; Honegger, Ursina; Mueller, Christian; Albus, Miriam; Zellweger, Michael; Liu, Yu‐Ching; Glarner, Noemi; Boeddinghaus, Jasper; Freese, Michael; Haaf, Philip; Gualandro, Danielle M.; Prepoudis, Alexandra; Leu, Kathrin; Schaerli, Nicolas; Belkin, Maria; Wildi, Karin; Puelacher, Christian; Shrestha, Samyut; Wussler, Desiree; Diebold, Matthias; Rentsch, Katharina; Buser, Andreas; du Fay de Lavallaz, Jeanne; Koechlin, Luca; Twerenbold, Raphael; Nestelberger, Thomas
title: Influence of renin‐angiotensin‐aldosterone system inhibitors on plasma levels of angiotensin‐converting enzyme 2
date: 2021-02-19
journal: ESC Heart Fail
DOI: 10.1002/ehf2.13249
sha: 0e321b408872b25c533f6a78ad1ec72e7ba1f244
doc_id: 731152
cord_uid: 4idl223r

AIMS: Concern has been raised that treatment with angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers may increase the expression of angiotensin‐converting enzyme 2 (ACE2), which acts as the entry receptor for SARS‐CoV‐2, and lead to an increased risk of death from SARS‐CoV‐2. We aimed to address this concern by evaluating the in vivo relationship of treatment with ACE inhibitors and angiotensin receptor blockers (ARB) with circulating plasma concentrations of ACE2 in a large cohort of patients with established cardiovascular disease (n = 1864) or cardiovascular risk factors (n = 2144) but without a history of heart failure. METHODS AND RESULTS: Angiotensin‐converting enzyme 2 was measured in 4008 patients (median age 68, 33% women, 31% on ACE‐inhibitors, 31% on ARB) using the SOMAscan proteomic platform (SomaLogic Inc, Colorado, USA). Plasma concentration of ACE2 was comparable in 1250 patients on ACE inhibitors (mean 5.99) versus patients without ACE inhibitors (mean 5.98, P = 0.54). Similarly, plasma concentration of ACE2 was comparable in 1260 patients on ARB (mean 5.99) versus patients without ARB (mean 5.98, P = 0.50). Plasma concentration of ACE2 was comparable in 2474 patients on either ACE inhibitors or ARB (mean 5.99) versus patients without ACE inhibitors or ARB (mean 5.98, P = 0.31). Multivariable quantile regression model analysis confirmed the lack of association between treatment with ACE inhibitors or ARB and ACE2 concentrations. Body mass index showed the only positive association with ACE2 plasma concentration (effect 0.015, 95% confidence interval 0.002 to 0.028, P = 0.024). CONCLUSIONS: In a large cohort of patients with established cardiovascular disease or cardiovascular risk factors but without heart failure, ACE inhibitors and ARB were not associated with higher plasma concentrations of ACE2.

The majority of deaths from the new severe acute respiratory syndrome coronavirus (SARS-CoV-2) occurred in patients with cardiovascular disease, who often were on chronic treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). 1 This epidemiological association together with experimental evidence that treatment with ACE inhibitors and ARB may increase the expression of angiotensin-converting enzyme 2 (ACE2), which acts as the entry receptor for SARS-CoV-2, has led to concern that ACE inhibitors and ARB may causally contribute to an increased risk of death from SARS-CoV-2 via increasing ACE2. 2 

We aimed to address this concern by evaluating the in vivo effect of treatment with ACE inhibitors and ARB on circulating plasma concentrations of ACE2 in a large cohort of patients with established cardiovascular disease (n = 1864) or cardiovascular risk factors (n = 2144), but without a history of heart failure (NCT01838148, ClinicalTrials.gov). 3 

This analysis was performed in a large prospective diagnostic study (ClinicalTrials.gov, NCT01838148) designed to advance the early detection of inducible myocardial ischaemia. Consecutive adult patients with symptoms possibly related to inducible myocardial ischaemia, who were referred for stress and rest myocardial perfusion imaging with single-photon emission computed tomography combined with computed tomography (MPI-SPECT/CT) to the University Hospital Basel (Basel, Switzerland), were recruited. All patients provided written informed consent. Clinical information, including patient characteristics, medication, symptoms, and cardiovascular history, was documented by physicians using standardized questionnaires and all medical files available. The study was approved by the local ethics committee and carried out according to the principles of the Declaration of Helsinki.

Of the 4219 patients enrolled in the study, ACE2 was measured in 4008 patients (median age 68 [interquartile range 60 to 76], 33% women, 31% on ACE inhibitors, 31% on ARB, baseline characteristics; see Table 1 ) using the SOMAscan proteomic platform version 4 (SomaLogic Inc, Colorado, USA). 4 In brief, SOMAscan uses a proprietary DNA-based aptamer technology to bind to the target protein with high 

Plasma concentration of ACE2 was comparable in 1250 patients on ACE inhibitors (mean 5.99) versus patients without ACE inhibitors (mean 5.98, P = 0.54; Figure 1 ). Similarly, plasma concentration of ACE2 was comparable in 1260 patients on ARB (mean 5.99) versus patients without ARB (mean 5.98, P = 0.50). Also, plasma concentration of ACE2 was comparable in 2474 patients on either ACE inhibitors or ARB (mean 5.99) versus patients without ACE inhibitors or ARB (mean 5.98, P = 0.31). Multivariable quantile regression model analysis adjusted for age, sex, body mass index, history of atrial fibrillation, diabetes, arterial hypertension, chronic obstructive pulmonary disease, myocardial infarction, coronary artery disease, percutaneous coronary intervention, and coronary artery bypass graft confirmed the lack of association between treatment with ACE inhibitors or ARB and ACE2 concentrations.

Body mass index was positively associated with ACE2 plasma concentration (effect 0.015, 95% CI: 0.002 to 0.028, P = 0.024), while age (À0.049, 95% CI: À0.065 to À0.034, P < 0.001), history of atrial fibrillation (À0.034, 95% CI: À0.062 to À0.006, P = 0.024), history of PCI (À0.041, 95% CI: À0.080 to À0.001, P = 0.042), and history of CABG (À0.052, 95% CI: À0.081 to À0.022, P < 0.001) were all negatively associated with ACE2 concentrations in the model.

This large observational study found no association between treatment with ACE inhibitors and/or ARB and circulating plasma concentrations of ACE2 in patients with established cardiovascular disease or cardiovascular risk factors, but without overt heart failure, representing the population most severely affected by SARS-CoV-2. This finding extends and corroborates similar observations regarding the lack of associations between treatment with ACE inhibitors and/or ARB on ACE2 plasma concentrations in two independent cohorts of patients with overt heart failure. 5, 6 The first study included 

1485 men and 537 women with heart failure in the derivation cohort and 1123 men and 575 women in the validation cohort, all enrolled in Europe. Median age was 69 years for men and 75 years for women. The second study included 2248 patients with heart failure enrolled in the USA. 5, 6 In contrast to the European heart failure study, 5 this study did not find male sex to be a significant predictor for ACE2 plasma levels. This might in part be explained by an upregulation of ACE2 expression in heart-failure patients, 7 potentially more so in men than in women. 8 Overall, these biomarker studies are in agreement with observational clinical studies documenting a lack of increased risk of severe illness in patients with COVID-19 treated with an ACE inhibitor or ARB. 9 However, ACE2 regulation by RAAS blockade might be different in patients with active COVID-19 compared with patients without, and further research is needed on this topic.

Taken together with emerging epidemiological data, 1 the three in vivo studies on ACE2 plasma concentrations support the concept that treatment with ACE inhibitors or ARB should not be withheld from patients at risk for infection with SARS-CoV-2, although this will need to be ultimately clarified by clinical trials. 10, 11 Some limitations should be considered. First, liquid chromatography coupled to mass spectrometry is the gold standard for plasma ACE2 analysis. Therefore, it is reassuring that SOMAscan measurements were shown to be largely in accordance with proteome and transcriptome measurements and the ACE2 aptamer specifically has been validated. 6, 12 Second, like previous studies, we measured circulating ACE2 plasma concentrations. The equilibrium between circulating and membrane-bound ACE2 remains, to our knowledge, incompletely understood.

In conclusion, in a large cohort of patients with established cardiovascular disease or cardiovascular risk factors but without heart failure, ACE inhibitors and ARB were not associated with higher plasma concentrations of ACE2.

Dr. Zimmermann reports research grants from the Freiwillige Akademische Gesellschaft Basel. Dr. Walter reports research grants from the Swiss Heart Foundation (FF19097 and F18111) and the Swiss Academy of Medical Sciences and Bangerter Foundation. Dr. Mueller has received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the Cardiovascular Research Foundation Basel, the University Hospital Basel, Abbott, Astra Zeneca, Beckman Coulter, Biomerieux, BRAHMS, Critical Diagnostics, Roche, Siemens, Singulex, and Sphingotec, as well as speaker/consulting honoraria from Abbott, Alere, Astra Zeneca, Bayer, Biomerieux, Boehringer Ingelheim, BMS, BRAHMS, Cardiorentis, Novartis, Roche, Sanofi, Siemens, and Singulex. All other authors declare that they have no conflict of interest with this study. All authors critically reviewed the manuscript and approved the final version for submission. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or approval of the manuscript.

Renin-angiotensin-aldosterone system blockers and the risk of Covid-19

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Using high-sensitivity cardiac troponin for the exclusion of inducible myocardial ischemia in symptomatic patients

Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensinaldosterone inhibitors

Clinical and proteomic correlates of plasma ACE2 (angiotensin-converting enzyme 2) in human heart failure

ACE2 gene expression is up-regulated in the human failing heart

Biospecimen Collection Source Site-NDRI, Biospecimen Collection Source Site-RPCI, Biospecimen Core Resource-VARI, Brain Bank Repository-University of Miami Brain Endowment Bank, Leidos Biomedical-Project Management, ELSI Study, Genome Browser Data Integration &Visualization-EBI, Genome Browser Data Integration &Visualization-UCSC Genomics Institute

Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) trial protocol

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the BRACE CORONA trial

Complementarity of SOMAscan to LC-MS/MS and RNAseq for quantitative profiling of human embryonic and mesenchymal stem cells

RAAS-inhibition and ACE2

This study was supported by the KTI, the Swiss Heart Foundation, the Cardiovascular Research Foundation Basel, the University Basel, the University Hospital Basel, Abbott, Roche, Schiller, Somalogic, and Singulex.